|
Oct 4
|
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
|
Oct 3
|
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
|
|
Jul 29
|
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
|
|
Jul 24
|
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
|
|
Jul 23
|
Telix Successfully Prices A$650 Million Convertible Bonds
|
|
Jul 23
|
Telix Announces A$600 Million Convertible Bonds Offering
|
|
Jun 17
|
Radiopharma specialist Telix pulls last-minute plug on $232m IPO
|
|
May 20
|
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
|
|
May 17
|
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
|
|
Apr 17
|
Q1 2024 Revenue and Business Update
|
|
Apr 16
|
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
|
|
Apr 15
|
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
|
|
Dec 18
|
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
|
|
Dec 6
|
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
|
|
Dec 4
|
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
|
|
Nov 29
|
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
|
|
Aug 23
|
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
|
|
Apr 26
|
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
|